

Respiratory diseases: Infection, inflammation, immunity.

Rajesh Patel*

Department of Pulmonary Medicine, *All India Institute of Medical Sciences (AIIMS)*, India

Introduction

This article details how influenza virus infection triggers significant airway inflammation and increases vulnerability to bacterial superinfections, primarily through the action of type I interferons. The research highlights the crucial role of these interferons in shaping the inflammatory response in the airways, contributing to disease severity and complications[1].

This article explores the sophisticated immune evasion strategies employed by *Mycobacterium tuberculosis* within the lung. Understanding these mechanisms is crucial for developing more effective vaccines and host-directed therapies, as the bacteria actively manipulates host immune responses to establish persistent infection and evade clearance[2].

This review provides a comprehensive overview of the current diagnostic methods for tuberculosis, highlighting both established and emerging technologies. It discusses the challenges in accurate and rapid diagnosis, especially in resource-limited settings, and emphasizes the need for innovative approaches to improve global TB control efforts[3].

This review delves into different phenotypes of airway inflammation in asthma, specifically addressing eosinophilic and non-eosinophilic forms. It discusses current therapeutic strategies targeting these distinct inflammatory pathways and explores future perspectives for more personalized and effective treatment approaches for severe asthma[4].

This review comprehensively outlines the immunopathological mechanisms underlying SARS-CoV-2 infection in the lung, detailing how the virus triggers severe inflammation and tissue damage. It covers the roles of various immune cells and cytokines, providing insights into the pathways that contribute to acute respiratory distress syndrome and other severe manifestations of COVID-19[5].

This article examines the promise and challenges of host-directed therapies (HDT) for tuberculosis, focusing on novel opportunities to modulate the host immune response against *Mycobacterium tuberculosis*. It highlights strategies aimed at improving treatment outcomes, reducing pathology, and shortening therapy duration, em-

phasizing the potential for HDTs to complement conventional antibiotic regimens[6].

This article investigates the significant impact of air pollution on the susceptibility and severity of respiratory viral infections. It describes how various air pollutants impair host immunity, exacerbate airway inflammation, and alter the respiratory microbiome, thereby increasing the risk of viral infections and worsening clinical outcomes[7].

This article elucidates the "vicious cycle" of airway infection and inflammation that characterizes bronchiectasis. It explains how impaired mucociliary clearance leads to persistent bacterial colonization, triggering chronic inflammation and further structural lung damage, perpetuating the cycle of infection and worsening respiratory function in affected individuals[8].

This article reviews the evidence linking early-life respiratory viral infections, particularly those caused by RSV and rhinovirus, to an increased risk of developing childhood asthma. It explores the mechanisms by which these early infections can induce airway remodeling, alter immune development, and establish a trajectory towards chronic inflammatory airway disease[9].

This review explores the critical concept of macrophage plasticity during tuberculosis infection, detailing how *Mycobacterium tuberculosis* manipulates macrophage phenotypes to survive and replicate. It highlights the dynamic interplay between the pathogen and host macrophages, which influences disease progression and immune evasion, offering potential targets for host-directed therapeutic interventions[10].

Conclusion

This collection of research explores critical aspects of respiratory diseases, focusing on inflammation, infection, and immune responses. Influenza virus infection is shown to drive significant airway inflammation and increase vulnerability to bacterial superinfections via type I interferons. Similarly, SARS-CoV-2 infection triggers severe lung inflammation and tissue damage through complex immunopathological mechanisms, leading to conditions like

*Correspondence to: Rajesh Patel, Department of Pulmonary Medicine, *All India Institute of Medical Sciences (AIIMS)*, India. E-mail: rajesh.patel@aiims.ac.in

Received: 05-May-2025, Manuscript No. AAJCRM-25-273; Editor assigned: 07-May-2025, Pre QC No. AAJCRM-25-273 (PQ); Reviewed: 27-May-2025, QC No. AAJCRM-25-273; Revised: 05-Jun-2025, Manuscript No. AAJCRM-25-273 (R); Published: 16-Jun-2025, DOI: 10.35841/AAJCRM-9.3.273

Acute Respiratory Distress Syndrome. The data also extensively covers tuberculosis, detailing how *Mycobacterium tuberculosis* employs sophisticated immune evasion strategies within the lung by manipulating host immune responses and macrophage plasticity for survival and replication. This highlights the potential of host-directed therapies to improve treatment outcomes and complement conventional antibiotic regimens. Challenges in accurate and rapid tuberculosis diagnosis, particularly in resource-limited settings, underscore the need for innovative diagnostic approaches. Beyond specific infections, several articles address broader issues of airway inflammation. Asthma involves distinct eosinophilic and non-eosinophilic inflammatory phenotypes, necessitating personalized therapeutic strategies. Bronchiectasis is characterized by a 'vicious cycle' of infection and inflammation due to impaired mucociliary clearance, leading to progressive lung damage. Furthermore, environmental factors like air pollution are shown to impair host immunity and exacerbate respiratory viral infections, while early-life viral infections significantly increase the risk of childhood asthma by altering immune development and inducing airway remodeling. Together, these studies emphasize the intricate interplay between pathogens, host immunity, and environmental factors in respiratory health.

References

1. Yanli Y, Xiangyu C, Xin L. *Influenza virus infection drives airway inflammation and susceptibility to bacterial superinfection via type I interferons*. *J Exp Med*. 2021;218:e20210871.
2. Gwendal DN, Chloé AJ, Rachel ATC. *Immune evasion strategies of Mycobacterium tuberculosis in the lung*. *Front Immunol*. 2022;13:891040.
3. Amruta R, Madhur S, Shruthi S. *Diagnostic landscape of tuberculosis: A narrative review*. *J Clin Tuberc Other Mycobact Dis*. 2022;27:100311.
4. Giovanni P, Giancarlo CS, Girolamo P. *Targeting eosinophilic and non-eosinophilic airway inflammation in asthma: Current and future perspectives*. *Int J Mol Sci*. 2020;21:8303.
5. John WW, Mark RD, Peter LMS. *Immunopathology of SARS-CoV-2 infection in the lung*. *Nat Rev Immunol*. 2022;22:673-688.
6. Marije CBH S, Robert JW, Frank VDV. *Host-directed therapies for tuberculosis: novel opportunities and challenges*. *Front Immunol*. 2020;11:585573.
7. Jinjun W, Li W, Wenhao L. *Impact of air pollution on respiratory viral infections*. *Int J Environ Res Public Health*. 2021;18:11822.
8. Jennifer JG, Robert JW, Michael RJ. *The vicious cycle of airway infection and inflammation in bronchiectasis*. *J Clin Med*. 2023;12:3757.
9. Sarah LJ, Rebecca JM, Adam JC. *Respiratory viral infections in early life and the risk of childhood asthma*. *Curr Opin Allergy Clin Immunol*. 2021;21:118-125.
10. Laura RV, Stephanie LS, Jennifer AH. *Macrophage plasticity in tuberculosis: A dynamic interplay with Mycobacterium tuberculosis*. *Trends Immunol*. 2022;43:885-899.

Citation: Patel R. *Respiratory diseases: Infection, inflammation, immunity*. *J Clin Resp Med*. 2025;09(03):273.